Ralf R. Schumann

Prof. Ralf R. Schumann


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FMFrank P Mockenhaupt
Frank P Mockenhaupt
JCJakob P. Cramer
Jakob P. Cramer
LHLutz Hamann
Lutz Hamann
MSMiriam S. Stegemann
Miriam S. Stegemann
JEJana Eckert
Jana Eckert
RSRalf R. Schumann
Ralf R. Schumann
Genetic host factors play a substantial role in susceptibility to and severity of malaria, which continues to cause at least one million deaths per year. Recently, members of the toll-like receptor (TLR) family have been shown to be involved in recognition of the etiologic organismPlasmodium falciparum: The glycosylphosphatidylinositol anchor induces signaling in host cells via TLR-2 and -4, whereas hemozoin-induced immune activation involves TLR-9. Binding of microbial ligands to the respective TLRs triggers the release of proinflammatory cytokines via the TLR/IL-1 receptor (TIR) domain and may contribute to the host response in malaria, including cytokine induction and fever. In a case-control study among 870 Ghanaian children, we examined the influence ofTLR-2,-4, and-9polymorphisms in susceptibility to severe malaria.TLR-2variants common in Caucasians and Asians were completely absent. However, we found a rare previously undescribed mutation (Leu658Pro), which impairs signaling via TLR-2. We failed to detect any polymorphisms within the TLR-9 Toll/IL-1 receptor domain. Two frequentTLR-9promoter polymorphisms did not show a clear association with malaria severity. In contrast, theTLR-4-Asp299Gly variant occurred at a high rate of 17.6% in healthy controls and was even more frequent in severe malaria patients (24.1%,P< 0.05). Likewise,TLR-4-Thr399Ile was seen in 2.4% of healthy children and in 6.2% of patients (P= 0.02).TLR-4-Asp299Gly andTLR-4-Thr399Ile conferred 1.5- and 2.6-fold increased risks of severe malaria, respectively. These findings suggest TLR4-mediated responses to malariain vivoandTLR-4polymorphisms to be associated with disease manifestation.

15 December 2001 in Blood
Verified
Journal Article
Open access
JZJanine Zweigner
Janine Zweigner
HGHans-Joachim Gramm
Hans-Joachim Gramm
OSOliver C. Singer
Oliver C. Singer
KWKarl Wegscheider
Karl Wegscheider
RSRalf R. Schumann
Ralf R. Schumann
Lipopolysaccharide-binding protein (LBP), an acute-phase protein recognizing lipopolysaccharide (LPS), catalyzes in low concentrations its transfer to the cellular LPS receptor consisting of CD14 and Toll-like receptor-4. It has recently been shown that high concentrations of recombinant LBP can protect mice in a peritonitis model from the lethal effects of LPS. To determine whether in humans the acute-phase rise of LBP concentrations can inhibit LPS binding to monocytes and induction of proinflammatory cytokines, LBP concentrations were analyzed in 63 patients meeting the American College of Chest Physicians/Society of Critical Care Medicine criteria of severe sepsis or septic shock and the ability of these sera to modulate LPS effects in vitro was assessed employing different assays. Transfer of fluorescein isothiocyanate–labeled LPS to human monocytes was assessed by a fluorescence-activated cell sorter–based method, and activation of monocytes was investigated by measuring LPS-induced tumor necrosis factor-α secretion in the presence of the sera. Anti-LBP antibodies and recombinant human LBP were instrumental for depletion and reconstitution of acute-phase sera and subsequent assessment of their modulating effects on LPS activity. Sera of patients with severe sepsis/septic shock exhibited a diminished LPS transfer activity and LPS-induced tumor necrosis factor-α secretion as compared with sera from healthy controls. LBP depletion of sepsis sera and addition of rhLBP resulting in concentrations found in severe sepsis confirmed that LBP was the major serum component responsible for the observed effects. In summary, the inhibition of LPS effects by high concentrations of LBP in acute-phase serum, as described here, may represent a novel defense mechanism of the host in severe sepsis and during bacterial infections.

20 July 2011 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
RSRalf R. Schumann
Ralf R. Schumann
LBP [LPS (lipopolysaccharide)-binding protein] was discovered approximately 25 years ago. Since then, substantial progress has been made towards our understanding of its function in health and disease. Furthermore, the discovery of a large protein family sharing functional and structural attributes has helped in our knowledge. Still, key questions are unresolved, and here an overview on the old and new findings on LBP is given. LBP is an acute-phase protein of the liver, but is also synthesized in other cells of the organism. While LBP is named after the ability to bind to LPS of Gram-negative bacteria, it also can recognize other bacterial compounds, such as lipopeptides. It has been shown that LBP is needed to combat infections; however, the main mechanism of action is still not clear. New findings on natural genetic variations of LBP leading to functional consequences may help in further elucidating the mechanism of LBP and its role in innate immunity and disease.

15 August 2004 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NSNicolas W. J. Schröder
Nicolas W. J. Schröder
HHHolger Heine
Holger Heine
CAChristian Alexander
Christian Alexander
MMMaria Manukyan
Maria Manukyan
JEJana Eckert
Jana Eckert
RSRalf R. Schumann
Ralf R. Schumann
LPS binding protein (LBP) is an acute-phase protein synthesized predominantly in the liver of the mammalian host. It was first described to bind LPS of Gram-negative bacteria and transfer it via a CD14-enhanced mechanism to a receptor complex including TLR-4 and MD-2, initiating a signal transduction cascade leading to the release of proinflammatory cytokines. In recent studies, we found that LBP also mediates cytokine induction caused by compounds derived from Gram-positive bacteria, including lipoteichoic acid and peptidoglycan fragments. Lipoproteins and lipopeptides have repeatedly been shown to act as potent cytokine inducers, interacting with TLR-2, in synergy with TLR-1 or -6. In this study, we show that these compounds also interact with LBP and CD14. We used triacylated lipopeptides, corresponding to lipoproteins of Borrelia burgdorferi, mycobacteria, and Escherichia coli, as well as diacylated lipopeptides, corresponding to, e.g., 2-kDa macrophage activating lipopeptide of Mycoplasma spp. Activation of Chinese hamster ovary cells transfected with TLR-2 by both lipopeptides was enhanced by cotransfection of CD14. Responsiveness of human mononuclear cells to these compounds was greatly enhanced in the presence of human LBP. Binding of lipopeptides to LBP as well as competitive inhibition of this interaction by LPS was demonstrated in a microplate assay. Furthermore, we were able to show that LBP transfers lipopeptides to CD14 on human monocytes using FACS analysis. These results support that LBP is a pattern recognition receptor transferring a variety of bacterial ligands including the two major types of lipopeptides to CD14 present in different receptor complexes.

13 May 2003 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
NSNicolas W. J. Schröder
Nicolas W. J. Schröder
CHCorinna Hermann
Corinna Hermann
LHLutz Hamann
Lutz Hamann
UGUlf B. Göbel
Ulf B. Göbel
THThomas Hartung
Thomas Hartung
RSRalf R. Schumann
Ralf R. Schumann

1 September 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
DOD.‐Y. Oh
D.‐Y. Oh
STStefan Taube
Stefan Taube
OHO. Hamouda
O. Hamouda
CKC. Kücherer
C. Kücherer
GPG. Poggensee
G. Poggensee
RSRalf R. Schumann
Ralf R. Schumann
Background. Toll-like receptors (TLRs) play an important role in the innate immune response to pathogens. TLR8 has been found to recognize RNA derive